💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Pyrophosphate

CHEMBL2110559 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Technetium pyrophosphate (99mTc-PYP) is a bone-seeking radiopharmaceutical that has gained renewed clinical importance for the non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) through myocardial scintigraphy, where it binds to amyloid fibrils in the myocardium. It is also used traditionally for bone scintigraphy and has been used in first-pass cardiac radionuclide ventriculography. Its high sensitivity and specificity for ATTR-CA when combined with serum protein electrophoresis has made it a key diagnostic tool for heart failure workup.

चिकित्सीय क्षेत्र

हृदय विफलता

क्रिया का तंत्र

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Technetium pyrophosphate (99mTc-PYP) is a bone-seeking radiopharmaceutical that has gained renewed clinical importance for the non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) through myocardial scintigraphy, where it binds to amyloid fibrils in the myocardium. It is also used traditionally for bone scintigraphy and has been used in first-pass cardiac radionuclide ventriculography. Its high sensitivity and specificity for ATTR-CA when combined with serum protein electrophoresis has made it a key diagnostic tool for heart failure workup.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Technetium Pyrophosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110559. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.